Prevalence and influencing factors of kidney impairment in middle-aged and elderly people living with HIV

WU Yanjie; WANG Shanling; HUA Tingting; XIE Yali; WANG Tingting; SHEN Weiwei; WANG Liangyou; LIN Haijiang; HE Na

doi:10.16462/j.cnki.zhjbkz.2025.08.002

Volume 29 Issue 8

Aug. 2025

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2025 > 29(8): 875-881

WU Yanjie, WANG Shanling, HUA Tingting, XIE Yali, WANG Tingting, SHEN Weiwei, WANG Liangyou, LIN Haijiang, HE Na. Prevalence and influencing factors of kidney impairment in middle-aged and elderly people living with HIV[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2025, 29(8): 875-881. doi: 10.16462/j.cnki.zhjbkz.2025.08.002

Citation:

WU Yanjie, WANG Shanling, HUA Tingting, XIE Yali, WANG Tingting, SHEN Weiwei, WANG Liangyou, LIN Haijiang, HE Na. Prevalence and influencing factors of kidney impairment in middle-aged and elderly people living with HIV[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2025, 29(8): 875-881. doi: 10.16462/j.cnki.zhjbkz.2025.08.002

Citation:

WU Yanjie, WANG Shanling, HUA Tingting, XIE Yali, WANG Tingting, SHEN Weiwei, WANG Liangyou, LIN Haijiang, HE Na. Prevalence and influencing factors of kidney impairment in middle-aged and elderly people living with HIV[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2025, 29(8): 875-881. doi: 10.16462/j.cnki.zhjbkz.2025.08.002

PDF( 814 KB)

Prevalence and influencing factors of kidney impairment in middle-aged and elderly people living with HIV

doi: 10.16462/j.cnki.zhjbkz.2025.08.002

1.
Department of Epidemiology, School of Public Health, Fudan University, Shanghai 200032, China
2.
Taizhou Prefectural Center for Disease Control and Prevention, Taizhou 318000, China

Funds:

Special Support Program for High Level Talents in Taizhou TZ2022-2

Natural Science Foundation of China 82173579

Key Disciplinary Program of Shanghai Public Health Action Plan GWVI-11.1-05

More Information

Corresponding author: LIN Haijiang, E-mail: 84800166@qq.com; HE Na, E-mail: nhe@fudan.edu.cn
Received Date: 2025-04-06
Rev Recd Date: 2025-06-12
Publish Date: 2025-08-10

Abstract

Abstract

Objective To investigate the prevalence and influencing factors of kidney impairment in middle-aged and elderly people living with human immunodeficiency virus(HIV; PLWH), and to provide scientific evidence for early prevention and intervention in this population. Methods A cross-sectional study was conducted based on the comparative HIV and aging research in Taizhou (CHART). PLWH aged 40 and above who participated in the baseline survey between January 2022 and July 2024 were enrolled. The estimated glomerular filtration rate (eGFR) was calculated using the chronic kidney disease epidemiology collaboration (CKD-EPI) formula. Descriptive statistical analysis was used to assess participants′ baseline characteristics and the prevalence of kidney impairment, while multivariable ordinal logistic regression was applied to identify influencing factors. Results A total of 692 middle-aged and elderly PLWH were included, comprising 527 males (76.16%) and 165 females (23.84%), with a median age of 56 years (IQR: 49-64). The prevalence of mild and moderate-to-severe kidney impairment was 23.55% (163/692) and 3.61% (25/692), respectively, with an overall prevalence of 27.17% (188/692). Multivariable ordinal logistic regression analysis revealed that age (55- < 70 years: aOR=3.75, 95% CI: 2.37-5.91; ≥70 years: aOR=29.47, 95% CI: 15.02-57.82), long-term use of two or more non-antiretroviral drugs (aOR=1.96, 95% CI: 1.15-3.35) and dyslipidemia (aOR=1.67, 95% CI: 1.12-2.48) were significantly associated with kidney impairment. Additionally, hyperuricemia was positively associated with kidney impairment, with a stronger association observed as severity increased. Compared to individuals with normal serum uric acid levels, those with hyperuricemia had higher odds of developing mild or greater kidney impairment (aOR=2.81, 95% CI: 1.62-4.88), and even greater odds of progressing to moderate-to-severe impairment (aOR=8.51, 95% CI: 3.44-21.07). Conclusions The prevalence of kidney impairment is relatively high in middle-aged and elderly PLWH, with mild impairment being the most common. Age, polypharmacy, dyslipidemia, and hyperuricemia are key influencing factors. It is recommended to regularly monitor renal function in middle-aged and elderly PLWH and implement comprehensive measures such as early screening, rational medication use, and metabolic regulation to reduce the risk of kidney damage.
- Elderly,
- Human immunodeficiency virus,
- Kidney impairment,
- Prevalence

FullText(HTML)

References(24)

References

[1]	Trickey A, Sabin CA, Burkholder G, et al. Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies[J]. Lancet HIV, 2023, 10(5): e295-e307. DOI: 10.1016/S2352-3018(23)00028-0.
[2]	Trachunthong D, Tipayamongkholgul M, Chumseng S, et al. Burden of metabolic syndrome in the global adult HIV-infected population: a systematic review and Meta-analysis[J]. BMC Public Health, 2024, 24(1): 2657. DOI: 10.1186/s12889-024-20118-3.
[3]	Collins LF, Sheth AN, Mehta CC, et al. The prevalence and burden of non-AIDS comorbidities among women living with or at risk for human immunodeficiency virus infection in the United States[J]. Clin Infect Dis, 2021, 72(8): 1301-1311. DOI: 10.1093/cid/ciaa204.
[4]	Verheij E, Boyd A, Wit FW, et al. Long-term evolution of comorbidities and their disease burden in individuals with and without HIV as they age: analysis of the prospective AGEhIV cohort study[J]. Lancet HIV, 2023, 10(3): e164-e174. DOI: 10.1016/S2352-3018(22)00400-3.
[5]	Diana NE, Naicker S. The changing landscape of HIV-associated kidney disease[J]. Nat Rev Nephrol, 2024, 20(5): 330-346. DOI: 10.1038/s41581-023-00801-1.
[6]	Drak D, Shamu TN, Heron JE, et al. Renal function and associated mortality risk in adults commencing HIV antiretroviral therapy in Zimbabwe[J]. AIDS, 2022, 36(5): 631-636. DOI: 10.1097/QAD.0000000000003153.
[7]	Lucas A, Wyatt CM. HIV at 40: kidney disease in HIV treatment, prevention, and cure[J]. Kidney Int, 2022, 102(4): 740-749. DOI: 10.1016/j.kint.2022.06.021.
[8]	Hughes K, Chang J, Stadtler H, et al. HIV-1 infection of the kidney: mechanisms and implications[J]. AIDS, 2021, 35(3): 359-367. DOI: 10.1097/QAD.0000000000002753.
[9]	Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2024). KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease[J]. Kidney Int, 2024, 105(4S): S117-S314. DOI: 10.1016/j.kint.2023.10.018.
[10]	中华人民共和国国家卫生健康委员会医政司. 肥胖症诊疗指南(2024年版)[J]. 中华消化外科杂志, 2024, 23(10): 1237-1260. DOI: 10.3760/cma.j.cn115610-20241017-00455. Department of Medical Administration, National Health Commission of the People's Republic of China. Guideline for diagnosis and treatment of obesity (2024 edition)[J]. Chin J Dig Surg, 2024, 23(10): 1237-1260. DOI: 10.3760/cma.j.cn115610-20241017-00455.
[11]	Centers for Disease Control and Prevention. Tobacco glossary[EB/OL]. (2017-08-29)[2025-06-08]. https://archive.cdc.gov/www_cdc_gov/nchs/nhis/tobacco/tobacco_glossary.htm.
[12]	Ampiah KA, Afari R, Osei-Assibey J, et al. A comparison of creatinine, cystatin C, and creatinine-cystatin C based equations in HIV/AIDS patients: a cross-sectional study[J]. Health Sci Rep, 2024, 7(12): e70263. DOI: 10.1002/hsr2.70263.
[13]	Hoang CQ, Nguyen HD, Vu HQ, et al. Determinants of risk factors for renal impairment among HIV-infected patients treated with tenofovir disoproxil fumarate-based antiretroviral regimen in southern Vietnam[J]. Biomed Res Int, 2020, 2020: 7650104. DOI: 10.1155/2020/7650104.
[14]	Asmelash D, Nigatie M. Chronic kidney disease and its associated factors in HIV-infected individuals: a comparison of antiretroviral therapy naïve and experienced patients[J]. Front Med, 2024, 11: 1455688. DOI: 10.3389/fmed.2024.1455688.
[15]	Mwemezi O, Ruggajo P, Mngumi J, et al. Renal dysfunction among HIV-infected patients on antiretroviral therapy in Dar es salaam, Tanzania: a cross-sectional study[J]. Int J Nephrol, 2020, 2020: 8378947. DOI: 10.1155/2020/8378947.
[16]	Liu F, Wang Y, Liu H, et al. Determinants and incidence of chronic kidney disease with tenofovir- based antiretroviral therapy regimens: a cohort study in HIV-infected adults in South China[J]. Curr HIV Res, 2022, 20(3): 242-250. DOI: 10.2174/1570162X20666220428105300.
[17]	Mendivil CO, Gnecco-González S, Herrera-Parra LJ, et al. MDRD is the eGFR equation most strongly associated with 4-year mortality among patients with diabetes in Colombia[J]. BMJ Open Diabetes Res Care, 2023, 11(4): e003495. DOI: 10.1136/bmjdrc-2023-003495.
[18]	Montano M, Oursler KK, Xu K, et al. Biological ageing with HIV infection: evaluating the geroscience hypothesis[J]. Lancet Healthy Longev, 2022, 3(3): e194-e205. DOI: 10.1016/s2666-7568(21)00278-6.
[19]	Kim JH, Jang H, Kim JH, et al. The incidence and risk factors of renal insufficiency among Korean HIV infected patients: the Korea HIV/AIDS cohort study[J]. Infect Chemother, 2022, 54(3): 534-541. DOI: 10.3947/ic.2022.0101.
[20]	康硕, 张瑄. 脂质肾毒性机制的研究进展[J]. 中国医学科学院学报, 2022, 44(5): 914-918. DOI: 10.3881/j.issn.1000.503X.14243. Kang S, Zhang X. Research progress in mechanism of lipid nephrotoxicity[J]. Acta Acad Med Sin, 2022, 44(5): 914-918. DOI: 10.3881/j.issn.1000.503X.14243.
[21]	Papantoniou E, Arvanitakis K, Markakis K, et al. Pathophysiology and clinical management of dyslipidemia in people living with HIV: sailing through rough seas[J]. Life, 2024, 14(4): 449. DOI: 10.3390/life14040449.
[22]	Li Y, Luo JQ, Liu XY, et al. Association between change in serum uric acid and rapid decline in kidney function in China[J]. Sci Rep, 2024, 14(1): 25140. DOI: 10.1038/s41598-024-76398-7.
[23]	Yanai H, Adachi H, Hakoshima M, et al. Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome, cardiovascular diseases and chronic kidney disease[J]. Int J Mol Sci, 2021, 22(17): 9221. DOI: 10.3390/ijms22179221.
[24]	Zhang BW, Wang JR, Liu N, et al. Association between polypharmacy and chronic kidney disease among community-dwelling older people: a longitudinal study in Southern China[J]. BMC Nephrol, 2024, 25(1): 169. DOI: 10.1186/s12882-024-03606-x.